13 results about "Infections site" patented technology

This invention relates to the field of bacterial infection treatment technology, and discloses an enzyme-responsive probe, its preparation method, and its applications. The probe of this invention constructs an enzyme-responsive "prodrug" structure by introducing cephalosporin derivative linker units that can be specifically cleaved by β-lactamases onto a hemicyanine optical framework. This structure remains optically and therapeutically inert in normal tissues, but is selectively activated at the site of infection by drug-resistant bacteria. When the probe contacts multidrug-resistant bacteria that overexpress β-lactamases, the linker units undergo enzymatic cleavage, releasing hemicyanine active molecules with near-infrared fluorescence emission and highly efficient photothermal conversion capabilities, achieving high-contrast fluorescence imaging and controllable photothermal sterilization of the infection focus. The probe of this invention has a simple synthetic route, mild conditions, and reliable purification methods, making it suitable for large-scale preparation, especially for the precise diagnosis and targeted photothermal synergistic treatment of superficial tissue infections such as bacterial keratitis.

The invention belongs to the technical field of radiopharmaceutical chemistry and clinical nuclear medicine, and particularly relates to an antibacterial peptide UBI 29-41 derivative containing proline as well as a preparation method and application thereof. The proline-containing antibacterial peptide UBI 29-41 derivative is labeled by radionuclide to obtain a radioactive preparation, and the radioactive preparation has high uptake in a bacterial infection part, has a good infection / non-target ratio, and can be specifically combined with bacteria. The radioactive preparation provided by the invention can be used as a novel radioactive drug for diagnosis of bacterial infection, and has good clinical popularization and application prospects and value.

The invention discloses an engineered polypeptide injection system and application thereof in targeted delivery of antibacterial peptides, and belongs to the technical field of biology. The engineered polypeptide injection system provided by the invention can accurately deliver the target polypeptide to a targeted infection site, reduce whole body exposure, reduce toxicity and give full play to the effect of the target polypeptide. The invention also provides application of the engineered polypeptide injection system in preparation of a product for eliminating mycobacteria in target cells and preparation of a product for preventing and / or treating lung diseases and / or symptoms caused by the mycobacteria, and target polypeptides Granulysin, HNP1, and LysA and / or LysB derived from mycobacteriophage D29 or MS6 are delivered to macrophages, so that the lung diseases and / or symptoms caused by the mycobacteria are prevented and treated, and the lung diseases and / or symptoms caused by the mycobacteria are prevented and treated. The mycobacteria can be effectively removed.

This invention relates to the field of biomedical technology, specifically to an antifungal nanoparticle, a combination drug, and its application. The antifungal nanoparticle is prepared by covalently linking the aptamer AU1 to drug-loaded silk fibroin nanoparticles via amide bonds. The mass ratio of the drug-loaded silk fibroin nanoparticles to the aptamer AU1 is 20:0.5~2.0. The antifungal nanoparticles of this invention are prepared by a desolvation method using voriconazole-loaded silk fibroin nanoparticles, and the targeting aptamer AU1 is attached to their surface using a carbodiimide chemical cross-linking method. This allows for specific recognition of Candida albicans, increasing drug accumulation at the infection site. Further combination with methylene blue-mediated photodynamic therapy can disrupt biofilm structures, enhance nanoparticle penetration, achieve synergistic bactericidal activity, and reduce systemic toxicity, providing a novel, highly effective, and low-toxicity treatment strategy for fungal biofilm infections.

The invention provides an infectious fever antibacterial scheme selection method and system based on multi-dimensional data, and belongs to the technical field of infectious disease diagnosis and treatment. The method comprises the following steps: step (1), identifying a fever type based on symptom and sign data and inspection data, and positioning a pathogen type, an infection site and severity; (2) generating candidate antibiotic schemes based on the antibiotic knowledge base and a guide rule engine; (3) adjusting the dosage according to the individual parameters of the patient, and generating a first scheme and an alternative scheme; through multi-dimensional data integration, infection types are rapidly identified, antibiotics recommended by a guide are matched, and an accurate and safe antibacterial scheme (including a first scheme and an alternative scheme) is generated according to individual conditions of patients.

To provide a method for treating implantable device infections. [Solution] The present invention relates to the field of phage therapy, and more particularly to providing phage-based compositions and methods for treating or preventing infections associated with implantable devices. The compositions may be administered directly to the infection site of the device, as a single dose and / or by other means as needed, potentially avoiding the need to replace the implantable device. The method may include (a) obtaining a biological sample from the subject; (b) culturing bacteria present in the biological sample; and (c) inoculating the cultured bacteria with a phage to lyse them.

The application provides a pH-responsive disintegrating amphiphilic dextran block polymer, a cationic antibacterial peptide nanodrug and application, utilizes the pH-responsive disintegrating amphiphilic dextran block polymer and the nanometer AMPs to utilize the electrostatic force, the N-B coordination bond force and the guanyl-π electron force to self-assemble into the cationic antibacterial peptide nanodrug, realizes the effective capture of the nanometer AMPs, not only improves the drug loading of the amphiphilic dextran block polymer, but also can protect the free amino group in the nanometer AMPs residue, improves the stability of the nanometer AMPs to protease, reduces the toxicity to normal cells and reduces the risk of hemolysis; and the cationic antibacterial peptide nanodrug gradually hydrolyzes under the weak acid environment of the infection site, so that the drug is enriched at the infection site and the bioavailability is improved, and a new solution is provided for overcoming the increasingly serious drug-resistant bacterial infection problem in clinic.

The invention belongs to the technical field of nano-drugs, and particularly relates to multifunctional honokiol nano-particles and a preparation method and application thereof.The honokiol nano-particles are prepared by using rhamnolipid modified chitosan as a carrier and loading honokiol; according to the nano-particles, an amido bond formed between rhamnolipid and chitosan can be subjected to targeted decomposition under the acidic condition of a bacterial infection part, and the released rhamnolipid can destroy a bacterial biofilm; further, permeation of the natural antibacterial agent honokiol and chitosan at the infected part is enhanced, and synergistic sterilization is realized; meanwhile, the planktonic bacteria re-adhesion resistance characteristic of rhamnolipid can inhibit the re-formation of a biofilm, the full-stage sterilization of'destroying the biofilm, killing bacteria in the film and inhibiting the re-adhesion of residual bacteria 'of the nanoparticles is finally realized, and the multifunctional honokiol nano platform is suitable for preventing and treating infectious diseases such as wound infection and bacterial peritonitis.

The invention discloses an antibacterial polypeptide high polymer material, a product containing the antibacterial polypeptide high polymer material, and a preparation method and application of the antibacterial polypeptide high polymer material, and belongs to the technical fields of high polymer materials, bacterial infection treatment and medicines. The preparation method of the antibacterial polypeptide high polymer material comprises the following steps: carrying out esterification reaction on enol and glutamic acid, and carrying out glutamic acid side group modification to obtain an R2-NCA monomer; taking R1-NH2 as an initiator, and reacting with the R2-NCA monomer to obtain polypeptide; primary amine or quaternary amine is modified to a polypeptide side group through click reaction of sulfydryl and double bonds, and finally the antibacterial polypeptide high polymer material is prepared. The antibacterial polypeptide high polymer material with a specific structure prepared by the method can effectively penetrate through and resist a biological membrane matrix barrier and specifically target bacterial membrane phospholipids; the compound shows excellent in-vivo antibacterial activity, can effectively inhibit biofilm-related infection and promote repair of infected parts, and has good treatment effect and application prospect.

The invention belongs to the technical field of radiopharmaceutical chemistry and clinical nuclear medicine, and particularly relates to a D-amino acid derivative as well as a preparation method and application thereof. A radioactive preparation obtained by labeling the D-amino acid derivative with radionuclide has high uptake in a bacterial infection part, is good in infection / non-target ratio, can be specifically combined with bacteria, and can distinguish aseptic inflammation. The radioactive preparation provided by the invention can be used as a novel radioactive drug for diagnosis of bacterial infection, and has good clinical popularization and application prospects and value.

The application provides an N-terminal fatty acid modified antibacterial peptide analogue and application thereof. Specifically, the antibacterial peptide analogue of the application has a fatty acid (dodecanoic acid, tetradecanoic acid or octadecanoic acid) modification at the N terminus of a super short peptide Lys-Gly-Lys to form a lipopeptide substance. The N-terminal fatty acid modified antibacterial peptide analogue described in the application can inhibit a plurality of pathogenic bacteria, in particular a plurality of mastitis pathogenic bacteria, has high inhibitory activity, and has a unique antibacterial mechanism, is not easy to induce drug resistance of pathogenic bacteria, can more safely inhibit bacteria, and can also solve the problem of antibiotic resistance easily produced in the treatment process of mastitis; further, the antibacterial peptide analogue of the application can also down-regulate the expression of body pro-inflammatory factors (for example, TNF-alpha, IL-6), and accelerate the repair of infected site tissues. The antibacterial peptide analogue of the application can effectively improve the cure rate of dairy cows and reduce economic losses.

The application belongs to the technical field of medical apparatus and discloses an ultrasonic antibacterial device for treating bone infection, which comprises a main control shell and a minimally invasive catheter. The main control shell is internally provided with a guide wire control module, an ultrasonic control module and a medium storage cavity. The minimally invasive catheter is of a double-layer structure and is internally provided with a guide wire. The front end of the minimally invasive catheter is provided with an annular ultrasonic medium cavity, which is used for filling ultrasonic medium solution. The ultrasonic medium cavity is internally provided with an ultrasonic generating assembly arranged in an annular array. The ultrasonic generating assembly is internally provided with a piezoelectric wafer, which is used for realizing electric-acoustic conversion to realize emission and acceptance of ultrasonic waves. When the device is used, the infection site is accurately positioned through the guide wire, ultrasonic waves are emitted through the ultrasonic generating assembly, and the structure of bacterial biofilm is destroyed through ultrasonic cavitation effect, so that the bacterial biofilm is removed and the antibacterial treatment effect is achieved. The device is suitable for bone infection treatment.

When the probiotic vesicle gel carrying the gene editing tool is applied to body surface infection parts of pathogenic bacteria of the same species as probiotics, DNA double-strand breakage of a pathogenic bacteria genome is caused, the probiotic vesicle gel has a bactericidal effect on wild pathogenic bacteria and drug-resistant pathogenic bacteria, and drug resistance of the pathogenic bacteria is avoided. The probiotic vesicle gel carrying the gene editing tool contains the gene editing tool, probiotic vesicles and gel. The probiotic vesicle gel carrying the gene editing tool is used for body surface or mucous membrane surface antibacterial treatment, has the advantages of being high in safety, capable of resisting drug-resistant bacteria, high in antibacterial effect, easy to remove and the like, and has a good treatment effect on secondary bacterial infection after ionizing radiation injury.